Capability, capacity, portfolio

Diverse Capabilities

Biologicals
  • Cell therapies
  • Immunotherapies
Small molecules
  • DNA damage repair
  • Epigenetics
  • Growth factors
  • Tumour microenvironment
Combinations
  • Mechanisms of resistance
  • Rational scientific design
Translational
  • Animal models
  • Biomarker expertise
  • Stratified medicine
  • Imaging
Regulatory requirements
  • Validated assays
  • Tissue sampling
  • GCP PK/PD lab sampling

 

Capacity of the Network

Since 2007, the ECMC infrastructure has enabled:

  • Over 700 trials
  • > 500 IMPs tested
  • Over 7,000 cancer patients recruited
  • Over 700 biomarker studies
  • 100 pharmaceutical partnerships

 

The ECMC Network has unique access to dedicated expertise:

  • Around 300,00 newly diagnosed cases per year
  • 42 NHS hospital trusts
  • Over 350 principal investigators
  • More than 50 dedicated clinical trials staff
  • 28 cancer types studied

 

Portfolio

ECMC funding continues to support a diverse portfolio of trial types, and a variety of treatment types across a range of cancers.

The number of studies is increasing every year, and the majority are led by an ECMC. Of the 806 studies hosted by the Network (as at 2012/13), 92% were led by an ECMC.

Top reasons for the importance of our studies include first-in-man for new agent or novel combination and first trial in a certain patient group.

Of new ECMC trials, 87% are on public clinical trials registers.